期刊文献+

微血管量在浸润性乳腺癌中的意义 被引量:5

THE VALUE OF MICROVESSEL DENSITY IN INVASIVE BREAST CARCINOMA
下载PDF
导出
摘要 探讨微血管量在浸润性乳腺癌中的意义。方法应用亲和素-生物素-过氧化物酶复合物(ABC)免疫组织化学方法对70例乳腺浸润性导管癌作荆豆素(UEA1)和第八因子(F8)染色,并对癌组织中的微血管计数。采用Logistic多因素回归分析法进行分析。结果淋巴结有转移组和无转移组间微血管计数有极显著的差异(P<0.0001)。淋巴结有转移组的微血管密度显著高于无淋巴结转移组(P<0.0001)。肿瘤的组织学分级与微血管计数及淋巴结转移显著相关(P<0.05和P<0.0001)。术后健在组患者和带癌生存、死亡组患者的微血管计数有显著差异(P<0.05)。结论浸润性乳腺癌内的微血管量是一个独立的有重要意义的预后因素,与淋巴结转移、患者的生存状况密切相关。 PURPOSE To study the value of microvessel density in invasive breast carcinoma. METHODS The expression of UEA1 and F8 was immunohistochemically detected by ABC method in 70 cases of primary invasive ductal carcinoma. RESULTS Multivariate analysis showed significant differences in microvessel density between patients with and without axillary lymph node metastasis. Patients with lymph node metastasis had increased microvessel density ( P <0.0001). There was signification association between histological grading and microvessel density and lymph node metastasis( P <0 05 and P <0 0001) There was a statistically significant difference in microvessel density between patients who were disease free and those who were not( P <0 05) CONCLUSIONS Microvessel density is an important and independent prognostic parameter for invasive breast carcinoma. Increased microvessel density is associated with lymph node metastasis and reduced survival.
出处 《中国癌症杂志》 CAS CSCD 1997年第2期86-89,共4页 China Oncology
关键词 微血管量 血管生成因子 乳腺癌 恶性肿瘤 breast neoplasms microvessel density angiogenesis factor lymphatic metastasis
  • 相关文献

同被引文献40

  • 1周磊.癌变过程中血管生成现象的动物实验研究[J].中国肿瘤临床,1994,21(2):128-130. 被引量:7
  • 2沈丹华.DNA图像分析的技术标准及其在肿瘤病理诊断中的应用[J].中国肿瘤临床,1996,23(12):898-901. 被引量:10
  • 3Weidner N, Folkman J, Pozza F,et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early -stage breast carcinoma[ J]. J Natl Cancer Inst, 1992,84(24) : 1875-1887.
  • 4Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast earcinoma and other solid tumors [ J]. Breast Cancer Res Treat, 1995,36(2) :169-180.
  • 5Bosari S, Lee AK, Delellis RA, et al. Microvessel quantitation and prognosis in invasive breast carcinoma [ J ]. Hum Pathol, 1992,23 (7) : 755-761.
  • 6Miliaras D, Kamas A, Kalekou H. Angiogenesis in invasive breast carcinoma: is it associated with parameters of prognostic significance [ J ]. Histopathology, 1995,26 (2) :165-169.
  • 7Fojo T,Wilkerson J. Bevaeizumab and breast cancer:the E2100 outlier[ J ]. Lancent Oncol,2010,11 ( 12 ) : 1117- 1119.
  • 8Petrelli F, Barni S. Bevacizumab in advanced breast cancer: an opportunity as second -line therapy [ M ]. Med Oncol,2010 : 14.
  • 9Fleming ST,Rastogi A.A comprehensive prognostic index to predict survival based on multiple comorbidities:a focus on breast cancer. Med Care, 1999,37(6):601-614.
  • 10Masood S.Prognostic factors in breast cancer. Breast J,1997,5(2):267-283.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部